Celiac.com Sponsor (A1):



Celiac.com Sponsor (A1-m):


  • You've found your Celiac Tribe! Join our like-minded, private community and share your story, get encouragement and connect with others.

    💬

    • Sign In
    • Sign Up
  • Jefferson Adams

    Influence of HLA-DQ2 and DQ8 on Severity in Celiac Disease

    Jefferson Adams
    0
    Reviewed and edited by a celiac disease expert.

    Photo: CC - rdecom
    Caption: Photo: CC - rdecom

    Celiac.com 03/14/2012 - A group of researchers recently studied the ways in which HLA-DQ2 and DQ8 might influence the severity of celiac disease. Specifically, the team wanted to study HLA-DQA1 and DQB1 profiles in adults with different forms of celiac disease, including adults with complicated and potential celiac disease, the most seriously affected, and those with the best preserved histologic end of the pathologic celiac spectrum.

    Photo: CC - rdecomThe researchers included F. Biagi, P.I. Bianchi, C. Vattiato, A. Marchese, L. Trotta, C. Badulli, A. De Silvestri, M. Martinetti, and G.R. Corazza. They are affiliated with the Coeliac Centre/First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Italy. 



    Celiac.com Sponsor (A12):






    Celiac.com Sponsor (A12-m):




    Patients with complicated celiac disease showed more HLA-DQB1*02 homozygosity than those with uncomplicated celiac disease.

    The team conducted HLA-DQA1 and DQB1 molecular typing for 218 adults with celiac disease. Of these, 169 had uncomplicated celiac disease, 27 had complicated celiac disease, and 22 had potential celiac disease. They used 224 healthy stem cell donors as a control group.

    The team analyzed HLA-DQA1 and DQB1 gene polymorphism using polymerase chain reaction sequence-specific primers and/or reverse polymerase chain reaction sequence-specific oligonucleotides. They found, as expected, that the frequency of HLA-DQB1*02 allele, DQB1*02 homozygosity, and DQB1*0302 gene were statistically different in the four groups.

    However, multivariate analysis showed that patients with potential celiac disease have a higher frequency of both HLA-DQB1*0302 and HLA-DQB1*0603 alleles, along with a reduced frequency of DQB1*02 homozygosity, as compared with patients with uncomplicated and complicated celiac disease.

    The increased frequency of DQB1*0302 coupled with the reduced frequency of DQB1*02 homozygosity in potential celiac disease supports the idea that variations in clinical/pathologic expressions of celiac disease might reflect different immune system triggers. This observation could impact the way in which celiac disease is understood and studied in the future.

    Source:

    0

    User Feedback

    Recommended Comments



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Jefferson Adams is Celiac.com's senior writer and Digital Content Director. He earned his B.A. and M.F.A. at Arizona State University, and has authored more than 2,500 articles on celiac disease. His coursework includes studies in science, scientific methodology, biology, anatomy, medicine, logic, and advanced research. He previously served as SF Health News Examiner for Examiner.com, and devised health and medical content for Sharecare.com. Jefferson has spoken about celiac disease to the media, including an appearance on the KQED radio show Forum, and is the editor of the book "Cereal Killers" by Scott Adams and Ron Hoggan, Ed.D.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-m):




  • Related Articles

    Roy Jamron
    Celiac.com 06/19/08 - Today in most modern countries, children are being raised in bacteria-free environments, yet studies are seeing a rising incidence of autoimmune disease and allergies. Previous studies have found that Finnish children are six times more likely to have type 1 diabetes and a five times higher rate of celiac disease than Russian children despite equal genetic susceptibility. Over-cleanliness and life-style may be promoting the higher prevalence of these disorders.
    The Diabimmune study, backed by the EU with EUR 6 million in financing, is asking whether by removing all bacteria, we are not actually weakening our children's immune ...

    Jefferson Adams
    Celiac.com 04/02/2009 - A recent study finds rates of celiac disease in Polish children are four times higher than estimated, and are only slightly lower than those of other northern European populations—at about 1 in 124 persons. Moreover, they found that symptoms in those diagnosed were typically absent, minimal or vague.
    To date, the only epidemiological studies of celiac disease undertaken in Poland had been carried out within limited areas and involved mainly symptomatic patients or high-risk groups. Until now, celiac was thought to affect about 1 in 400 children in the country. A team of researchers based in Poland recently set out to determine a...

    Jefferson Adams
    Celiac.com 05/07/2014 - Current treatment for celiac disease is to eat only foods which are gluten-free. But, what about foods processed to remove gluten? Is it safe for people with celiac disease to eat foods that have been processed to remove gluten?
    Processing may render gluten-containing foods technically safe celiac patients, but so far live safety testing can only be performed on actual patients, not in laboratory computer models.
    A team of researchers recently set out to test the safety of germinated rye sourdough in a celiac disease model based on the adoptive transfer of prolamin-primed memory T cells into lymphopenic mice. The research...

    Jefferson Adams
    Celiac.com 04/24/2015 - Dr. Falk Pharma and Zedira recently announced the start of phase I clinical trials for the drug candidate ZED1227, a direct acting inhibitor of tissue transglutaminase.
    The small molecule targets the dysregulated transglutaminase within the small intestine in order to dampen the immune response to gluten which drives the disease process. This approach will offer patients additional safety when applied in support of a ‘mostly’ gluten-free diet thereby improving the quality-of-life of millions of people.
    In 2011, Dr. Falk Pharma licensed the rights for ZED1227 in Europe and took charge of pre-clinical and clinical development of ...